Abstract: Selective and irreversible inhibitors of neuronal isoform of nitric oxide synthase catalyzed production of nitric oxide are L-ornithine or L-lysine derivatives having the formula ##STR1## wherein Q is H or (CH.sub.2).sub.r CH.sub.3 where r ranges from 0 to 15, x is 1 or 2, R" is CH.sub.2 or C(H) (CH.sub.2).sub.y CH.sub.3 where y ranges from 0 to 5, R' is CH.sub.2 or C(H) (CH.sub.2).sub.z CH.sub.3 where z ranges from 0 to 5, R is H or (CH.sub.2).sub.s CH.sub.3 where s ranges from 0 to 5, with none or only one of R, R' and R" providing an alkyl substituent on ornithine or lysine moiety, R.sup.III is OH or is an alkoxy group of 1 to 6 carbon atoms or is an amino acid or peptide attached in amide linkage through its free .alpha.-amino group, and R.sup.IV is --H or an acyl group of 1 to 6 carbon atoms or is an amino acid or peptide attached in amide linkage through its free .alpha.-carboxylate group, and mixtures thereof with corresponding D-isomers. A preferred compound is N.sup.

Abstract: Methods and pharmaceutical compositions of matter are disclosed and claimed relating to cardioprotective effect mediated by delta (.delta.) opioid receptor agonists or more specifically delta-1 (.delta..sub.1)-opioid receptor agonists. Further, methods drawn to reducing ischemic damage to organs and tissues having delta (.delta.) opioid receptor agonists or more specifically delta-1 (.delta..sub.1)-opioid receptors are disclosed and claimed. Specifically, methods and pharmaceutical compositions of matter are taught as a means of providing cardioprotective treatment through the administration of delta (.delta.) opioid receptor agonists or more specifically delta-1 (.delta..sub.1)-opioid receptor agonists, such as TAN67(-). Said methods and pharmaceutical compositions are envisioned as a means of reducing myocardial infarction arising from the onset and sequelae of myocardial ischemia.

Abstract: Mammals are treated for infections or for conditions associated with pathologically proliferating mammalian cell growth (for example, certain cancers, restenosis, benign prostatic hypertrophy) by administration of a manipulator of nitrosative stress to selectively kill or reduce the growth of the microbes or helminths causing the infection or of host cells infected with the microbes or of the pathologically proliferating mammalian cells. Novel agents include .alpha.-alkyl-S-alkyl-homocysteine sulfoximines wherein the .alpha.-alkyl contains 2 to 8 carbon atoms, and the S-alkyl-contains 1 to 10 carbon atoms. In another invention herein, mammals in need of increased nitrosative stress defenses are treated, e.g., humans at risk for a stroke because of having had a transient ischemic attack, are treated.

Abstract: A method for the detection of the presence or absence of antibodies which bind to antigens of an NMA virus indicative of Chronic Fatigue Immune Deficiency Syndrome is disclosed. This method comprises contacting a solution containing antigens of an NMA virus with a biological sample of a patient and detecting the antibody-antigen complexes. Methods for detection of the presence or absence of antigens or nucleic acid sequences specific to an NMA virus are also disclosed. A substantially purified preparation of an NMA virus and a human cell line chronically infected with an NMA virus are also disclosed.

Abstract: Administration of argininosuccinate synthetase activity reducing agents, e.g., argininosuccinate synthetase induction blocking agents (e.g., antibiotics that bind to DNA sequences present in the upstream regulatory region of the argininosuccinate synthetase gene, such as mithramycin) and argininosuccinate synthetase inhibitors (e.g., L-citrulline antagonists such as methyl citrulline and L-aspartate antagonists such as D-aspartate) is useful to prevent or treat sepsis or cytokine-induced systemic hypotension, is useful in the treatment of sepsis or cytokine-induced systemic hypotension to restore vascular sensitivity to the effects of .alpha..sub.1 -adrenergic agonists, and is useful to suppress an immune response, e.g., in treating inflammation. In one embodiment, certain argininosuccinate synthetase activity reducing agents are used together with arginine antagonists to treat sepsis or cytokine induced hypotension.

Abstract: Inhibitors of nitric oxide formation from arginine useful for treating hypotension, inflammation, stroke and to restore vascular contractile sensitivity to the effects of .alpha..sub.1 adrenergic agonists are physiologically active compounds including N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties or monoalkyl carbon-substituted N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties, having the formula ##STR1## wherein R is (CH.sub.2).sub.y CH.sub.3 or H, R' is CH.sub.2 or C(H)(CH.sub.2).sub.y CH.sub.3, and R" is CH.sub.2 or C(H)(CH.sub.2).sub.y CH.sub.3, with y ranging from 0 to 5, and x is 0 or 1 and wherein none or only one of R, R' and R" provides an alkyl substituent on ornithine or lysine moiety, and wherein Q is a heme binding moiety and/or a sulfur-containing binding moiety and Q' is --NH.sub.2 when there is a double bond between the omega carbon and Q and Q' is .dbd.

Abstract: Administration of argininosuccinate synthetase activity reducing agents, e.g., argininosuccinate synthetase induction blocking agents (e.g., antibiotics that bind to DNA sequences present in the upstream regulatory region of the argininosuccinate synthetase gene, such as mithramycin) and argininosuccinate synthetase inhibitors (e.g., L-citrulline antagonists such as methyl citrulline and L-aspartate antagonists such as D-aspartate) is useful to prevent or treat sepsis or cytokine-induced systemic hypotension, is useful in the treatment of sepsis or cytokine-induced systemic hypotension to restore vascular sensitivity to the effects of .alpha..sub.1 -adrenergic agonists, and is useful to suppress an immune response, e.g., in treating inflammation. In one embodiment, certain argininosuccinate synthetase activity reducing agents are used together with arginine antagonists to treat sepsis or cytokine induced hypotension.

Abstract: A method for the detection of the presence or absence of antibodies which bind to antigens of an NMA virus Deficiency is disclosed. This method comprises contacting a solution containing antigens of an NMA virus with a biological sample of a patient and detecting the antibody-antigen complexes. Methods for detection of the presence or absence of antigens or nucleic acid sequences specific to an NMA virus are also disclosed. A substantially purified preparation of an NMA virus and a human cell line chronically infected with an NMA virus are also disclosed.

Abstract: Inhibitors of nitric oxide formation from arginine useful for treating hypotension, inflammation, stroke and to restore vascular contractile sensitivity to the effects of .alpha..sub.1 -adrenergic agonists are physiologically active compounds including N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties or monoalkyl carbon-substituted N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties, having the formula ##STR1## wherein R is (CH.sub.2).sub.y CH.sub.3 or H, R' is CH.sub.2 or C(H)(CH.sub.2).sub.y CH.sub.3, and R" is CH.sub.2 or C(H)(CH.sub.2).sub.y CH.sub.3, with y ranging from 0 to 5, and x is 0 or 1 and wherein none or only one of R, R' and R" provides an alkyl substituent on ornithine or lysine moiety, and wherein Q is alkyl having 1 to 5 carbon atoms, and physiologically acceptable acid addition salts thereof.

Abstract: Inhibitors of nitric oxide formation from arginine useful for treating hypotension, inflammation, stroke and to restore vascular contractile sensitivity to the effects of .alpha..sub.1 adrenergic agonists are physiologically active compounds including N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties or monoalkyl carbon-substituted N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties, having the formula ##STR1## wherein R is (CH.sub.2).sub.y CH.sub.3 or H, R' is CH.sub.2 or C(H)(CH.sub.2).sub.y CH.sub.3, and R" is CH.sub.2 or C(H)(CH.sub.2).sub.y CH.sub.3, with y ranging from 0 to 5, and x is 0 or 1 and wherein none or only one of R, R' and R" provides an alkyl substituent on ornithine or lysine moiety, and wherein Q is a heme binding moiety and/or a sulfur-containing binding moiety and Q' is --NH.sub.2 when there is a double bond between the omega carbon and Q and Q' is .dbd.

Abstract: Inhibitors of nitric oxide formation from arginine useful for treating hypotension, inflammation, stroke and to restore vascular contractile sensitivity to the effects of .alpha..sub.1 adrenergic agonists are physiologically active compounds including N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties or monoalkyl carbon-substituted N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties, having the formula ##STR1## wherein R is (CH.sub.2).sub.y CH.sub.3 or H, R' is CH.sub.2 or C(H) (CH.sub.2).sub.y CH.sub.3, and R" is CH.sub.2 or C(H) (CH.sub.2).sub.y CH.sub.3, with y ranging from 0 to 5, and x is 0 or 1 and wherein none or only one of R, R' and R" provides an alkyl substituent on ornithine or lysine moiety, and wherein Q is a heme binding moiety and/or a sulfur-containing binding moiety and Q' is --NH.sub.2 when there is a double bond between the omega carbon and Q and Q' is .dbd.

Abstract: An in vitro method for the production of interferon is set forth. The method involves the culture of monocytes with a new DA15 peptide produced in Daudi cell lines in response to stimulation with interferon gamma.

Abstract: Inhibitors of nitric oxide formation from arginine useful for treating hypotension, inflammation, stroke and to restore vascular contractile sensitivity to the effects of .alpha..sub.1 -adrenergic agonists are physiologically active compounds including N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties or monoalkyl carbon-substituted N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties, having the formula ##STR1## wherein R is (CH.sub.2).sub.y CH.sub.3 or H, R' is CH.sub.2 or C(H)(CH.sub.2).sub.y CH.sub.3, and R" is CH.sub.2 or C(H)(CH.sub.2).sub.y CH.sub.3, with y ranging from 0 to 5, and x is 0 or 1 and wherein none or only one of R, R' and R" provides an alkyl substituent on ornithine or lysine moiety, and wherein Q is alkyl having 1 to 5 carbon atoms, and physiologically acceptable acid addition salts thereof.

Abstract: A method of inducing bone growth in a living animal consists of implanting in the soft tissue or bone of the animal a bone morphogenetic protein-free, ceramic consisting of a calcium phosphate which is at least partially resorbable, and leaving the ceramic in place until new bone growth is induced.

Abstract: A method of treating a body fluid so as to inactivate protozoa in said fluid comprises mixing the body fluid with an effective amount of a photosensitizing agent which will bind to cell-free protozoa and/or protozoan-infected cells, and then exposing the resulting mixture to visible light to inactivate the protozoa. An apparatus for use in the method includes at least one container which contains a body fluid containing protozoa and an effective amount of a photosensitizing agent to bind to the protozoa. The apparatus has at least one wall which is permeable to visible light.

Abstract: A method of treating a body fluid which is to be infused so as to inactivate any enveloped viruses in said fluid comprises mixing the body fluid with an effective amount of a photosensitizing agent which will bind to the viruses and/or virus infected cells and photosensitize them, and then exposing the resulting mixture to visible light to excite and inactivate the viruses. An apparatus for use in the method includes at least one container which contains an effective amount of the photosensitizing agent and which has at least one wall which is permeable to visible light. A number of photosensitizing agents which can be used in the method also are disclosed.

Abstract: A method is disclosed for preventing or treating cerebral vasospasms such as those which usually follow subarachnoid hemorrhage. The method comprises administering to the animal a safe and effective amount of nicorandil to prevent or treat the vasospasm.

Abstract: An attachment for a scintillation camera to enable the camera to be used for measurement of bone mineral mass includes a grid holder adapted to be attached to the camera, a grid mounted on the grid holder and adapted to lie directly in front of the camera when the grid holder is attached to the camera, and an arm attached at one end to the grid holder and, at the other end, including a source holder. The source holder is entirely closed except that it defines an aperture directed toward the grid. The source holder is at least 50 cm from the grid, and the grid is focussed on the source holder.

Abstract: A method of inactivating viruses comprises bringing the viruses into contact with an effective amount of a photosensitizing agent which will bind to the viruses and/or virus infected cells, and then exposing the resulting mixture to visible light to excite and inactivate the viruses.

Abstract: Novel biotinylated nucleotides have a chemically cleavable linker arm between a biotin and an organic basic group. They are useful in a method of isolating target macromolecules from crude physiological mixtures. The biotinylated nucleotides are bound via their organic basic groups to macromolecules having an affinity for the target macromolecules and brought into contact with the target macromolecules to form a biotinylated nucleotide-affinity macromolecule - target macromolecule complex. The complex thus obtained is brought into contact with immobilized avidin whereupon the biotin moeity binds to the avidin. The complex and avidin are washed to remove undesired substances and then the chemically cleavable bond in the nucleotide is cleaved to obtain the affinity-macromolecule - target macromolecule complex from which the target macromolecule can be obtained.